← Back

Wire · opportunities

Cosentyx Gains FDA Approval for Adults With Polymyalgia Rheumatica

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at empr.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA has approved Cosentyx (secukinumab) as the first anti-IL-17A biologic treatment for adults with polymyalgia rheumatica who cannot tolerate or respond inadequately to corticosteroids, based on positive results from a Phase 3 trial.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now position your treatment options to include a newly FDA-authorised biologic that offers an alternative to corticosteroids in PMR. This approval opens a sales gate for therapies targeting inflammatory disorders beyond traditional steroid treatments.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalbiologic-drugspolymyalgia-rheumaticaimmunologynovartis